Zum Hauptinhalt springen Zur Suche springen Zur Hauptnavigation springen
Beschreibung
The refinement of a chemical process to the point where it becomes both cost and time efficient can be seen as "art." In a competitive environment where pharmaceutical companies are under ever increasing pressure to bring new drugs more quickly to the market, ways need to be found to provide bulk supplies of drug candidates as quickly as possible and to design manufacturing routes, which are robust, economical and environmentally firendly. This monograph is divided into 9 chapters, each one concentrating on a single class of drug candidates of chemistry development and describing the routes explored and the optimizations made to each drug candidate, inluding the discovery of applicable new chemistry and the elucidation of reaction mechanism.

From the contents:

  • Efairenz(R), a Non-Nucleoside Reverse Transciptase Inhibitor (NNRTI), and a Previous Structurally Related Development Candidate
  • CCR5 Receptor Antagonist
  • 5α-Reductase Inhibitors - The Finsteride Story
  • Rizatriptan (Maxalt(R)): A 5-HT1D Receptor Agonist
  • SERM: Selective Estrogen Receptor Modulator
  • HIV Integrase Inhibitor: Raltegravir
  • Cyclopentane-Based NK1 Receptor Antagonist
  • Glucokinase Activator
  • CB1R Inverse Agonist - Taranabant
The refinement of a chemical process to the point where it becomes both cost and time efficient can be seen as "art." In a competitive environment where pharmaceutical companies are under ever increasing pressure to bring new drugs more quickly to the market, ways need to be found to provide bulk supplies of drug candidates as quickly as possible and to design manufacturing routes, which are robust, economical and environmentally firendly. This monograph is divided into 9 chapters, each one concentrating on a single class of drug candidates of chemistry development and describing the routes explored and the optimizations made to each drug candidate, inluding the discovery of applicable new chemistry and the elucidation of reaction mechanism.

From the contents:

  • Efairenz(R), a Non-Nucleoside Reverse Transciptase Inhibitor (NNRTI), and a Previous Structurally Related Development Candidate
  • CCR5 Receptor Antagonist
  • 5α-Reductase Inhibitors - The Finsteride Story
  • Rizatriptan (Maxalt(R)): A 5-HT1D Receptor Agonist
  • SERM: Selective Estrogen Receptor Modulator
  • HIV Integrase Inhibitor: Raltegravir
  • Cyclopentane-Based NK1 Receptor Antagonist
  • Glucokinase Activator
  • CB1R Inverse Agonist - Taranabant
Details
Erscheinungsjahr: 2010
Genre: Chemie, Mathematik, Medizin, Naturwissenschaften, Technik
Rubrik: Naturwissenschaften & Technik
Medium: Buch
Inhalt: XVI
282 S.
265 s/w Illustr.
31 farbige Illustr.
38 s/w Tab.
334 Illustr.
ISBN-13: 9783527324705
ISBN-10: 3527324704
Sprache: Englisch
Einband: Gebunden
Autor: N Yasuda
Redaktion: Nobuyoshi Yasuda
Herausgeber: Nobuyoshi Yasuda
Auflage: 1/2011
Hersteller: Wiley-VCH GmbH
Verantwortliche Person für die EU: Wiley-VCH GmbH, Boschstr. 12, D-69469 Weinheim, product-safety@wiley.com
Maße: 245 x 175 x 19 mm
Von/Mit: N Yasuda
Erscheinungsdatum: 27.10.2010
Gewicht: 0,694 kg
Artikel-ID: 129581758

Ähnliche Produkte